|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,264 GBX | +1.20% |
|
+0.77% | +15.70% |
| May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
| May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
By Sabela Ojea
AstraZeneca PLC said Thursday that its Lynparza drug has been approved in China to treat advanced prostate cancer.
The pharmaceutical giant said the approval by China's National Medical Products Administration was based on a subgroup analysis of the profound phase 3 trial.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
06-24-21 0223ET
| 1st Jan change | Capi. | |
|---|---|---|
| +15.70% | 236B | |
| +32.95% | 700B | |
| +26.51% | 569B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B |
ASTRAZENECA PLC 
